0%
0%
0%
0%
0%
About OptiNose, Inc
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Ramy A. Mahmoud
Website
optinose.com
Headquarters
Yardley
Employees
141
Founded
2000
ISIN
US68404V1008
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
OptiNose: Maximum OptimismGood afternoon.
I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company.
Summary:
Technical analysis:
On the chart, we can see the completion of cor
OPTN Technical Analysis 🧙OptiNose Inc is a US-based specialty pharmaceutical company which focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, which utilizes proprietary breath powered exhala
OPTN Technical Analysis 🧙OptiNose Inc is a US-based specialty pharmaceutical company which focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, which utilizes proprietary breath powered exhala
OPTN Follow Your Nose!OPTN risk to reward ratio looks phenomenal right now. We have horizontal price support, uptrend price support, horizontal RSI support, hidden bullish RSI divergence, and a recent gap fill. Based on the prior signals, I'm targeting +30% gain in less than 2 weeks to fill the gap at $6.40. This setu
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
